| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1978) |
| Entry Type: | Small molecule |
| Molecule Category: | Parent Prodrug |
| ATC: | M01AB02 |
| UNII: | 184SNS8VUH |
Structure
| InChI Key | MLKXDPUZXIRXEP-MFOYZWKCSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C20H17FO3S |
| Molecular Weight | 356.42 |
| AlogP | 4.37 |
| Hydrogen Bond Acceptor | 2.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 4.0 |
| Polar Surface Area | 54.37 |
| Molecular species | ACID |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 25.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Cyclooxygenase inhibitor | PubMed |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Isomerase
|
- | 80000 | - | - | - | |
|
Enzyme
Lyase
|
- | - | - | 77900 | - | |
|
Enzyme
Oxidoreductase
|
- | 16000 | - | - | - | |
|
Ion channel
Ligand-gated ion channel
Glycine receptor
|
380 | - | - | - | - | |
|
Secreted protein
|
- | - | 570 | - | - | |
|
Transcription factor
Nuclear receptor
Nuclear hormone receptor subfamily 2
Nuclear hormone receptor subfamily 2 group B
Nuclear hormone receptor subfamily 2 group B member 1
|
- | 82900 | - | - | - | |
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 241 | |
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC22 family of organic cation and anion transporters
|
- | - | - | - | 27 | |
|
Transporter
Primary active transporter
ATP-binding cassette
ABCB subfamily
|
- | 63690 | - | - | - |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Colorectal Neoplasms | 3 | D015179 | ClinicalTrials |
| Colorectal Neoplasms | 3 | D015179 | ClinicalTrials |
| Adenomatous Polyposis Coli | 3 | D011125 | ClinicalTrials |
| Precancerous Conditions | 3 | D011230 | ClinicalTrials |
| Fragile X Syndrome | 2 | D005600 | ClinicalTrials |
| Carcinoma, Squamous Cell | 2 | D002294 | ClinicalTrials |
| Leukemia, Myeloid, Acute | 2 | D015470 | ClinicalTrials |
| Melanoma | 2 | D008545 | ClinicalTrials |
| Breast Neoplasms | 2 | D001943 | ClinicalTrials |
| Fibromatosis, Aggressive | 2 | D018222 | ClinicalTrials |
Related Entries
MCS
Scaffolds
Side Effects from Label
Side Effects (PT)
| Side effects | Relative Frequency (%) | Labels | |
|---|---|---|---|
| Gastrointestinal disorders Gastrointestinal pain | 10.0 |
Adverse Reactions
System Organ Classification (SOC)
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 38194-50-2 |
| ChEBI | 9352 |
| ChEMBL | CHEMBL15770 |
| DrugBank | DB00605 |
| DrugCentral | 2534 |
| EPA CompTox | DTXSID4023624 |
| FDA SRS | 184SNS8VUH |
| Human Metabolome Database | HMDB0014743 |
| Guide to Pharmacology | 5425 |
| KEGG | C01531 |
| PubChem | 1548887 |
| SureChEMBL | SCHEMBL4202 |
| ZINC | ZINC00537805 |
CONTENTS